nebivolol


Also found in: Medical, Wikipedia.
Translations

nebivolol

n nebivolol m
References in periodicals archive ?
7) Use of nebivolol: nebivolol is a [beta]1-adrenergic receptor antagonist, a third-generation beta-adrenergic blocker, with vasodilator and antioxidant properties [188, 189].
Exclusion criteria in our study were as follows: i) any coexisting cardiac disease, such as heart failure, arrhythmia and STEMI; ii) patients with chest pain present for more than 4 hours, iii) any evidence of liver, kidney or respiratory disease; iv) malignancy; v) any infectious, inflammatory or infiltrative disorder; vi) recent use (within 48 h) of any drug with anti-oxidant properties, such as nebivolol, carvedilol, vitamins E and C, and acetylcysteine; and vii) pregnant women, viii) surgical procedures or trauma in the preceding 3 months, ix) regular alcohol use or alcohol use within 48 hours.
In line with the results from the present study, we observed rbcNOS activation and NO formation, but no effect on RBC deformability, with the eNOS-activator nebivolol in our assay (Reidenbach et al.
Adverse events were mild, and they were reported by 23% of the nebivolol group and 24% of the placebo group.
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-0 against recommending approval of nebivolol for reducing mortality and cardiovascular hospitalizations in patients with heart failure.
They also anticipate greater contributions from such new products as Campral for alcohol addiction and nebivolol, a beta-blocker heart treatment that is subject to FDA clearance.
For example, nebivolol (a vasodilating and highly selective [[beta].
Gresele, "Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
Findings from the SENIORS trial were more promising: Treatment with nebivolol reduced both mortality and readmission rates for elderly patients with HE with similar benefits for those with reduced and preserved EE22 Overall, beta-blockers appear to be a reasonable choice for heart rate and/or BP control in patients who have HFPEF and atrial fibrillation or hypertension.
The effects of nebivolol on P wave duration and dispersion in patients with coronary slow flow.
Flack participated in one of the nebivolol studies, but said he is not a consultant to nor speaker for the makers of the drug.